Melanoma Cutaneous Malignancies Liquid Biopsy Radiological Response Predict Outcomes Following Discontinuation Targeted Therapy Patients BRAF Mutated Melanoma LORENZA DI GUARDOa GIOVANNI RANDONa FRANCESCA CORTIa VIVIANA VALLACCHIb ALESSANDRA RAIMONDIa GIOVANNI FUCÀa MARTA BINIa ANDREA MAURICHIc ROBERTO PATUZZOa GIANFRANCESCO GALLINOc ILARIA MATTAVELLIc ROBERTA RUGGERIc MARTINA ANGId MARA COSSAe BARBARA VALERIe CAROLINA CIMMINIELLOa MARIO SANTINAMIc LICIA RIVOLTINIb FILIPPO DE BRAUDaf MONICA RODOLFOb MICHELE DEL VECCHIO aDepartment Medical Oncology bUnit Immunotherapy Human Tumors cMelanoma Sarcoma Surgery Unit dOcular Oncology Service Department Surgery eDepartment Pathology Fondazione Istituto di Ricovero e Cura Carattere Scientiﬁco Istituto Nazionale dei Tumori Milan Italy fOncology HematoOncology Department University Milan Milan Italy Contributed equally Cosenior authors Disclosures potential conﬂicts end article Key Words Melanoma cid129 BRAF cid129 Target therapy ABSTRACT Background Outcomes patients metastatic melanoma discontinuing BRAFtargeted therapy cumulative toxicity sustained response unknown Materials Methods This retrospective case series analysis conducted single Cancer Center Italy included patients BRAF mutated metastatic melanoma treated BRAF inhibitor single agent combination MEK inhibitor June 1 2011 January 1 2020 interrupted treatment cumulative toxicity achieving complete response CR longlasting partial response PR 12 months Results We included 24 patients median treatment duration 594 months 95 conﬁdence interval CI 554634 range 1288 CR PR achieved 71 29 patients respectively At median followup treatment discontinuation 378 months 95 CI 337419 radiological 12month progressionfree survival discontinuation dPFS rate 708 95 CI 548916 24month dPFS rate 583 95 CI 416818 Baseline patient tumor characteristics treatment duration best response signiﬁcantly impact dPFS Patients CR nega tive circulating tumor DNA ctDNA time discontinuation signiﬁcantly improved dPFS compared patients residual disease ctDNA positivity p 007 No patient CR undetectable ctDNA experi enced progression Conclusion The risk progression high patients sustained sensitivity BRAFMEK inhibitors Inte gration liquid biopsy clinical trials investigating optimal management patients sustained sensitiv ity BRAFMEK inhibitors warranted The Oncologist 20212610791084 Implications Practice Outcomes patients metastatic melanoma discontinuing BRAFtargeted therapy cumulative toxicity unknown This study analyzed patients sustained responses median treatment duration 594 months Twelve 24month progressionfree survival following discontinuation 708 583 respectively Complete response negative circulating tumor DNA time discontinuation promising prognostic biomarkers setting INTRODUCTION BRAF inhibitors combination MEK inhibitors standard care patients metastatic melanoma harboring BRAF V600EK mutations 1 Longterm followup analysis trials upfront dabrafenib single agent combination trametinib showed 49 16 patients experiencing complete CR partial response PR Correspondence Lorenza Di Guardo MD Department Medical Oncology Fondazione Istituto di Ricovero e Cura Carattere Scientiﬁco Istituto Nazionale dei Tumori Via Giacomo Venezian 1 20133 Milan Italy Telephone 390223902469 email lorenzadiguardoistitutotumori miit Received April 1 2021 accepted publication July 23 2021 published Online First September 21 2021 httpdxdoiorg 101002onco13926 This open access article terms Creative Commons AttributionNonCommercialNoDerivs License permits use distribution medium provided original work properly cited use noncommercial modiﬁcations adapta tions The Oncologist 20212610791084 wwwTheOncologistcom 2021 The Authors The Oncologist published Wiley Periodicals LLC behalf AlphaMed Press 1080 Discontinuation Target Therapy Melanoma Table 1 Patients characteristics Table 2 Univariate analysis dPFS n 24 n 56 4363 Variable Gender Characteristic Age median IQR yr Gender Female Male ECOG PS 0 1 Synchronous metastases Yes No Stage M1a M1b M1c M1d Number metastatic sites 1 2 Baseline LDH Low High Previous lines treatment metastatic disease 0 1 Treatment received Vemurafenib Dabrafenib Vemurafenibcobimetinib Dabrafenibtrametinib 12 50 12 50 24 100 0 3 13 21 87 7 29 7 29 8 33 2 8 9 37 15 63 21 87 3 13 21 87 3 13 14 58 1 4 1 4 8 33 Abbreviations ECOG PS Eastern Cooperative Oncology Group perfor mance status IQR interquartile range LDH lactate dehydrogenase respectively free disease progression PD 5 years 2 Continuation targeted therapy PD unacceptable toxicity recommended unknown patients safely taken targeted therapy achieving tumor response The outcomes following discontinuation patients achieving longterm BRAFMEK inhibitors response currently unknown biomarkers avail able guide decisionmaking process setting Interestingly patients stage III melanoma detect able baseline postsurgery circulating tumor DNA ctDNA strongly predicts relapse 3 suggesting evaluation ctDNA means liquid biopsy exploitable biomarker melanoma adjuvant metastatic settings 4 In present study report clinical outcomes patients metastatic mela noma treated BRAFMEK inhibitors interrupted treatment achieving longlasting objective response exploring role ctDNA assessed time discontinuation biomarker postdiscontinuation progressionfree survival PFS dPFS 2021 The Authors The Oncologist published Wiley Periodicals LLC behalf AlphaMed Press Female Male Age Synchronous metastases No Yes Stage M1a M1b M1c M1d Number metastatic sites 1 2 Baseline LDH Normal High Previous lines treatment metastatic disease None One Treatment Mono Combo Dose reduction No Yes Treatment duration Time best response Best response CR PR dPFS HR 95 CI Ref 0807 02452660 0997 09511045 Ref 2318 049310900 Ref 9792 112785090 2709 027926269 11715 1003136738 Ref 1081 06671752 Ref 0552 00704320 Ref 1157 02495363 Ref 1394 04254571 Ref 1914 05606546 1014 098210479 1087 10051175 Ref 3118 088610979 p value 727 889 287 076 752 571 853 583 301 392 037 063 Abbreviations CR complete response dPFS postdiscontinuation progressionfree survival LDH lactate dehydrogenase PR partial response Ref reference MATERIALS AND METHODS Patient Population We retrieved data patients metastaticunresectable melanoma harboring BRAF V600EK mutations treated BRAF V600 inhibitor combination MEK inhib itor discontinued treatment cumulative toxicities achieving longlasting 12 months CR PR Baseline clini copathological treatment characteristics collected ret rospectively dPFS deﬁned time treatment discontinuation PD death The primary outcome measure dPFS 12 24 months Exploratory outcome measures dPFS according RECIST best response liquid biopsy The study approved Fondazione Istituto di Ricovero e Cura Carattere Scientiﬁco IRCCS Istituto Nazionale dei Guardo Randon Corti et al 1081 A B C Tumori di Milano Institutional Review Board study ID INT 23 20 conducted according ethical principles medi cal research involving human subjects adopted Declara tion Helsinki All patients signed written Informed Consent Liquid Biopsy Liquid biopsies performed time targeted therapy discontinuation radiological evaluation conﬁrmed PD patients melanoma bearing BRAF V600E mutation CtDNA isolated QIAamp Circulating Nucleic Acid kit Qiagen Hilden Germany 2 ml plasma obtained peripheral blood collected EDTA Vacutainer tubes BD stored cid180cid3C CtDNA eluted 45 μl buffer AVE 75 μl ctDNA digital polymerase chain reaction dPCR analysis QuantStudio 3D Digital PCR System ThermoFisher Scientiﬁc Waltham MA Quantiﬁcation abundance BRAF V600E mutated allele c1799T A corresponding wild type allele determined commercially available TaqMan dPCR Liquid Biopsy Assay Hs000000004_rm ThermoFisher Waltham Massachusetts USA analyzing dPCR data QuantStudio 3D Analysis Suite Cloud Software The mutation cutoff threshold set background signal analysis plasma samples healthy controls n 21 set zero copies mutated allele Positivity patients ranged 3 100 copiesmL PCR speciﬁcity sensitivity deﬁned titration experiments assaying dilutions BRAF mutated DNA heterozygous melanoma cell line wildtype DNA dilutions water BRAF mutated DNA The limit detec tion 01 mutated allele fraction given DNA input 5 ng Levels circulating BRAF V600E variants expressed mutant allele frequency calculated copies mutantcopies mutant copies wildtype cid4 100 Statistical Analysis Continuous data summarized mean median values Categorical data summarized frequency percent age Eventfree survival evaluated KaplanMeier method The logrank test compare survival func tions Hazard ratios calculated univariate Coxs pro portional hazards regression model All statistical tests twotailed p 05 considered statistically signiﬁcant Figure 1 KaplanMeier curve dPFS according radiological best response A KaplanMeier curve dPFS according ctDNA time discontinuation target therapy B Kaplan Meier curve dPFS according radiological best response ctDNA time discontinuation targeted therapy Dark green indicates patients CR undetectable ctDNA time discontinuation Orange line indicates patients PR patients CR detectable ctDNA C Abbreviations CR complete response ctDNA circulating tumor DNA dPFS postdiscontinuation progressionfree survival PR partial response wwwTheOncologistcom 2021 The Authors The Oncologist published Wiley Periodicals LLC behalf AlphaMed Press 1082 Discontinuation Target Therapy Melanoma No PD PD CR PR ctDNA ctDNA ID14 ID02 ID24 ID22 ID08 ID15 ID11 ID12 ID13 ID09 ID01 ID20 ID19 ID21 ID18 ID07 ID05 ID16 0 20 40 60 Time months 80 100 120 Figure 2 Swimmer plot targeted therapy treatment duration followup ctDNAevaluable patients Dark light violet rows indicate patients PR CR respectively Black green dots indicate patients ctDNA positive negative treat ment discontinuation respectively Dark light blue rows indicate patients experienced PD patients free progression data cutoff respectively Abbreviations CR complete response ctDNA circulating tumor DNA PD progressive disease PR partial response ID13 ID11 ID22 ID19 10 F A M 05 00 10 F A M 05 00 F A M 10 05 00 S 1mo P 3mo S 1mo P 4mo S 3mo P 7mo S ID9 ID20 ID16 ID24 10 F A M 05 00 10 F A M 05 00 F A M 10 05 00 10 F A M 05 00 10 F A M 05 00 S 2mo 5mo P 10mo S 3mo P 11mo S P 32mo S P 15 mo Figure 3 Longitudinal monitoring ctDNA disease progression therapy discontinuation The timepoint ctDNA assessment matches radiological disease progression P followed individual progressionfree survival discontinuation patient ID19 liquid biopsy unevaluable time disease progression Black dots represent positive ctDNA green dots represent negative ctDNA Abbreviation ctDNA circulating tumor DNA MAF mutant allele frequency P time radiological disease progression S time discontinuation RESULTS Patient Population Among 453 patients BRAF mutated metastaticmela noma referring Fondazione IRCCS Istituto Nazionale dei Tumori Hospital June 1 2011 January 1 2020 24 fulﬁlled inclusion criteria Patients baseline demographics disease characteristics treatment received detailed Table 1 Outcomes Following Discontinuation Median treatment duration 594 months 95 CI 554634 range 1288 Best response CR PR achieved median time 53 95 CI 2021 The Authors The Oncologist published Wiley Periodicals LLC behalf AlphaMed Press Guardo Randon Corti et al 1083 2482 months At time discontinuation 17 71 7 29 patients achieved CR PR respectively At median follow 378 months 95 CI 337419 treatment discontinuation total 11 458 patients experienced PD Clinical information patterns disease progression detailed supplemental online Table 1 No patient experienced symptomatic PD All patients alive time present analysis Two 11 patients dis played involvement new organ sites Twelvemonth dPFS rate 708 95 CI 548916 24 month dPFS rate 583 95 CI 416818 Median time PD treatment discontinuation 104 months 95 CI 69138 Neither baseline clinico pathological characteristics treatment duration ﬂuenced risk PD time best response signiﬁcantly associated dPFS univariate analysis HR 1087 95 CI 10051175 p 037 Table 2 We nonsigniﬁcant trend worse dPFS patients interrupting treatment residual dis ease 12month dPFS rate 429 95CI 182100 compared interrupted treatment achieving RECISTdeﬁned CR 12month dPFS rate 824 95 CI 661100 logrank p 063 Fig 1A Prognostic Implications Liquid Biopsy Time Discontinuation Plasma samples 18 patients BRAF V600E melanoma available treatment discontinuation assessable ctDNA analysis Six patients denied consent plasma sampling translational studies including patients tissue BRAF V600K mutation Individual clinical course patients available ctDNA time discontinuation shown Figure 2 Longitudinal monitoring ctDNA patients experiencing disease progression therapy dis continuation shown Figure 3 Out evaluable patients positive ctDNA time discontinuation ﬁve patients maintained detectable ctDNA followup Patient ID9 undetectable ctDNA time discontinua tion interrupted targeted therapy residual brain metastases There signiﬁcant worse dPFS group patients positive ctDNA 12month dPFS rate 636 95 CI 407995 compared patients negative ctDNA time treatment discontinu ation 12month dPFS rate 857 95 CI 633100 logrank p 039 Fig 1B Of note patients CR negative ctDNA time discontinuation experienced PD study period 12 month dPFS 100 compared patients radiological residual disease ctDNA positivity 12 month dPFS rate 538 95 CI 326891 logrank p 007 Fig 1C Activity Retreatment BRAFMEK Inhibitors Among patients relapsed clinical followup avail able 10 patients Six patients received combination BRAF MEK inhibitors patient treated nivolumab All patients resuming targeted therapy achieved RECIST objective response patients achieving CR DISCUSSION In patients sustained sensitivity BRAF MEK targeted therapy cumulative toxicity burden impair quality life requiring dose reductionsdrug holidays However complete radiological response clinically undetectable minimal residual disease encompassed heterogeneous cellular populations drive relapse 5 Several retrospective studies summarized 6 addressed outcomes patients dis continuing targeted therapy reasons PD achieving CR evidence disease following com bined treatments surgical resection metastases 610 Collectively studies highlighted heterogeneous clini cally meaningful risk progression ranging 20 100 following median time 1 3 years treatment Herein report risk progression high 35 71 CR PR respectively Differently reported studies focused hyper selected population including patients clearly retained sensitivity BRAFMEK inhibitors outlined highest reported median treatment duration cid55 years fol lowup discontinuation cid538 months Baseline fac tors Eastern Cooperative Oncology Group performance status lactate dehydrogenase level tumor burden associated dPFS unlikely retain prognostic impact dPFS patients reached deep durable responses Moreover duration drug exposure interfere postdiscontinuation risk PD reﬂect underlying aggressive biol ogy disease However report length exposure targeted therapy achieving RECIST response associ ated reduced risk progression following discontinuation Therefore optimal duration targeted therapy clearing minimal residual disease patients experience CR deserves investigation The achievement RECIST CR crucial determinant prolonged PFS treatment discontinuation Even small sample size prevented mal demonstration impact best response postdis continuation progression 6 17 35 patients achieving CR eventually experienced PD study period com pared 5 7 71 patients achieving PR Recently negative ctDNA time treatment discontinuation emerged promising biomarker dPFS patients inter rupting targeted therapy sustained CR reﬁne identiﬁcation patients lower risk relapse 6 Therefore assessed combination complete radiological response ctDNA negativity reliably predict dPFS RECIST response Intriguingly patients achieved radiological CR tested negative ctDNA treatment discontinuation relapsed Importantly combination RECIST CR negative ctDNA time dis continuation displayed high sensitivity represents main goal biomarkers informing deescalation strategies In fact low amounts ctDNA responder patients pres ence nonshedding tumors central nervous CNS metastases generate false negative results wwwTheOncologistcom 2021 The Authors The Oncologist published Wiley Periodicals LLC behalf AlphaMed Press 1084 Discontinuation Target Therapy Melanoma preventing incorporation liquid biopsy clinical practice risk omission therapy meaningful impact survival targeted therapy patients sustained response BRAFMEK inhibitors Accordingly report patient discontinued therapy brain metas tases achieving partial response tested negative ctDNA time discontinuation highlighting potential sub optimal sensitivity liquid biopsy patients CNS involve ment 11 Limitations study related retrospective design small sample size lack clinical vali dation liquid biopsy setting CONCLUSION The development clinical grade monitoring ctDNA liquid biopsies appears importance studies particular clinical setting Therefore translation results daily clinical practice recommended Pro spective trials aimed deﬁne role liquid biopsy info rming clinical decisionmaking patients sustained responses BRAFMEK inhibitors warranted ACKNOWLEDGMENTS We acknowledge technical contribution Paola Deho AUTHOR CONTRIBUTIONS Conceptiondesign Lorenza Di Guardo Giovanni Randon Francesca Corti Filippo De Braud Michele Del Vecchio REFERENCES Provision study material patients Giovanni Randon Francesca Corti Vivianna Vallacchi Marta Bini Andrea Maurichi Roberto Patuzzo Gianfrancesco Gallino Ilaria Mattavelli Roberta Ruggeri Martina Angi Mara Cossa Barbara Valeri Carolina Cimminiello Mario Santinami Licia Rivoltini Monica Rodolfo Collection andor assembly data Giovanni Randon Francesca Corti Vivi ana Vallacchi Marta Bini Andrea Maurichi Roberto Patuzzo Gianfrancesco Gallino Ilaria Mattavelli Roberta Ruggeri Martina Angi Mara Cossa Barbara Valeri Carolina Cimminello Mario Santinami Licia Rivoltini Monica Rodolfo Data analysis interpretation Lorenza Di Guardo Giovanni Randon Francesca Corti Alessandra Raimondi Giovanni Fucà Manuscript writing Lorenza Di Guardo Giovanni Randon Francesca Corti Alessandra Raimondi Giovanni Fucà Marta Bini Final approval manuscript Lorenza Di Guardo Giovanni Randon Fran cesca Corti Viviana Vallacchi Alessandra Raimondi Giovanni Fucà Marta Bini Andrea Maurichi Roberto Patuzzo Gianfrancesco Gallino Ilaria Mattavelli Roberta Ruggeri Martina Angi Mara Cossa Barbara Valeri Carolina Cimminiello Mario Santinami Licia Rivoltini Filippo De Braud Monica Rodolfo Michele Del Vecchio DISCLOSURES Filippo De Braud Ignyta Pﬁzer Amgen Novartis Daiichi Sankyo BristolMyers Squibb Dompee Pierre Fabre Roche Octimet Incyte Teofarma EMD Serono Merck Sharp Dohme Menarini H Novartis Roche Merck Sharp Dohme Ignyta Medimmune Nektar BristolMyers Squibb Merck Serono Bayer Celgene GlaxoSmithKline Boeringher Ingelheim Eli Lilly Co Pﬁzer Servier RF Michele Del Vecchio Novartis BristolMyers Squibb Merck Sharp Dohme Sanoﬁ Pierre Fabre CA H The authors indicated ﬁnancial relationships CA Consultingadvisory relationship RF Research funding E Employment ET Expert testimony H Honoraria received OI Ownership interests IP Intellectual property rights inventorpatent holder SAB Scientiﬁc advisory board 1 Michielin O van Akkooi ACJ Ascierto PA et al Cutaneous melanoma ESMO Clinical Practice Guidelines diagnosis treatment followup Ann Oncol 20193018841901 2 Robert C Grob JJ Stroyakovskiy D et al Five year outcomes dabrafenib plus trametinib metastatic melanoma N Engl J Med 2019381 626636 3 Tan L Sandhu S Lee RJ et al Prediction monitoring relapse stage III melanoma cir culating tumor DNA Ann Oncol 201930804814 5 Rambow F Rogiers A MarinBejar O et al Toward minimal residual diseasedirected ther apy melanoma Cell 2018174843855e819 6 Warburton L Meniawy TM Calapre L et al Stopping targeted therapy complete responders advanced BRAF mutant melanoma Sci Rep 20201018878 7 Tolk H Satzger I Mohr P et al Complete remission metastatic melanoma BRAF inhibitor treatment happens discon tinuation Melanoma Res 201525362366 4 Lee JH Long GV Boyd S et al Circulating tumour DNA predicts response antiPD1 anti bodies metastatic melanoma Ann Oncol 2017 2811301136 8 Carlino MS Vanella V Girgis C et al Cessa tion targeted therapy complete response BRAFmutant advanced melanoma A case series Br J Cancer 201611512801284 9 Desvignes C Abi Rached H Templier C et al BRAF inhibitor discontinuation rechallenge advanced melanoma patients complete initial treatment response Melanoma Res 2017 27281287 10 Vanhaecke C Deilhes F Chanal J et al BRAF V600 inhibitor discontinuation complete response advanced melanoma A retrospective analysis 16 patients Br J Dermatol 2017177 e94e95 11 Lee JH Menzies AM Carlino MS et al Lon gitudinal monitoring ctDNA patients melanoma treated immune checkpoint inhibitors Clin Cancer Res 2020264064 brain metastases See httpwwwTheOncologistcom supplemental material available online 2021 The Authors The Oncologist published Wiley Periodicals LLC behalf AlphaMed Press